Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate
Recruiting
Phase 1
Phase 2
Interventional Study
Primary Aldosteronism
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 12 (estimated)
- Sponsor
- University Medical Center Groningen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to investigate the uptake characteristics of \[18F\]CETO in adrenal tissue in patients with two different subtypes of primary aldosteronism. The main questions it aims to answer are:
* What are the uptake characteristics of \[18F\]CETO in adrenal tissue in patients with primary aldosteronism?
* What is the concordance between the adrenal vein sampling and the \[…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* above 18 years
* Biochemically established diagnosis of PA\*
* Completion of standard diagnostic work-up of PA\*
* Able to follow and understand instructions to participate in the study
* Able to give written informed consent.
Exclusion Criteria:
* diabetes mellitus (i.e., H…
Contacts